Luminopia

Luminopia is a commercial-stage digital therapeutics company founded in 2016 by Scott Xiao, Dean Travers, and Alex Wendland. The company originated from the founders' time at Harvard University, motivated by a personal connection to amblyopia, commonly known as "lazy eye." Scott Xiao, the CEO, was inspired by a college classmate's struggle with the condition, which led him to explore how technology could offer a more engaging and effective treatment than traditional methods like eye-patching. This led to the development of a prototype in collaboration with Boston Children's Hospital and MIT researchers.

The company's core business revolves around its lead product, Luminopia, the first FDA-approved digital therapeutic for amblyopia. It operates on a prescription-based model, where eye care professionals prescribe the treatment, which is then dispensed through partner pharmacies like CoAssist Pharmacy. The target clients are children aged 4 to 12 diagnosed with amblyopia associated with vision imbalance (anisometropia) and/or mild eye crossing (strabismus). The company has secured partnerships with major health plans, like Anthem Blue Cross and Blue Shield, to ensure insurance coverage for eligible patients.

Luminopia's product is a software-based therapy delivered via a commercially available virtual reality (VR) headset. Patients watch therapeutically modified TV shows and movies for one hour a day, six days a week. The software uses proprietary, dual-acting algorithms to alter the video content in real-time, rebalancing the visual input to the brain. This process encourages the use of the weaker eye and trains the brain to combine input from both eyes, a method known as binocular therapy. A key feature is the extensive content library of over 700 hours of popular children's shows from partners like Sesame Workshop, Nickelodeon, and PBS Kids, which enhances patient engagement and adherence to the therapy. Clinical trials have demonstrated that this treatment can significantly improve visual acuity in as little as 12 weeks.

The company has achieved significant milestones, including receiving FDA De Novo approval in October 2021 for children aged 4-7, a first for a VR-based therapeutic for any medical condition. In April 2025, the FDA cleared a label expansion to include patients aged 8 to 12, based on real-world evidence. Luminopia has successfully raised a total of $37.8 million in funding through multiple rounds, including a $16 million Series A round in June 2023 led by U.S. Venture Partners. Key investors include ShangBay Capital, Sony Innovation Fund, The Vertical Group, and Boston Children's Hospital.

Keywords: digital therapeutics, amblyopia, pediatric ophthalmology, virtual reality therapy, neuro-visual disorders, FDA-approved, binocular vision, prescription software, vision therapy, medical device